Document Type
Article
Publication Date
4-1-2019
Abstract
AIM: Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity?
PATIENTS & METHODS: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively.
RESULTS: Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and 1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival was 99.3% for patients ≥55 years with class 1A, T1-T2 tumors and 55.0% for class 2B, SLN-positive, T1-T2 tumors.
CONCLUSION: The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy.
Recommended Citation
Vetto, John T.; Hsueh, Eddy C.; Gastman, Brian R.; Dillon, Larry D.; Monzon, Federico A.; Cook, Robert W.; Keller, Jennifer; Huang, Xin; Fleming, Andrew; Hewgley, Preston; Gerami, Pedram; Leachman, Sancy; Wayne, Jeffrey D.; Berger, Adam C.; and Fleming, Martin D., "Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling." (2019). Department of Surgery Faculty Papers. Paper 170.
https://jdc.jefferson.edu/surgeryfp/170
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
PubMed ID
30691297
Language
English
Comments
This article has been peer reviewed. It is the author’s final published version in Future Oncology, Volume 15, Issue 11, April 2019, Pages 1207-1217.
The published version is available at https://doi.org/10.2217/fon-2018-0912. Copyright © Vetto et al.